The PEERLESS II trial will evaluate the clinical outcomes of Inari Medical's FlowTriever System compared to anticoagulation in pulmonary embolism patients. Positive results from the trial could lead to increased adoption of the FlowTriever System, potentially boosting Inari Medical's revenues and stock price. The trial's outcome is directly related to the company's product and its potential market share, making it highly relevant and important for investors.